Leemans C, Braakhuis B, Cancer RB-N reviews, 2011 undefined. The molecular biology of head and neck cancer. nature.comCR Leemans, BJM Braakhuis, RH Brakenhoff Nature reviews cancer, 2011•nature.com. 2010; 11:9–22.

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92.

Article  PubMed  Google Scholar 

Magnes T, Wagner S, Kiem D, Weiss L, Rinnerthaler G, Greil R, et al. Prognostic and predictive factors in advanced head and neck squamous cell carcinoma. Int J Mol Sci. 2021;22:4981.

Article  CAS  PubMed  Google Scholar 

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro GJ, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck KEYNOTE-048: a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–28.

Article  CAS  PubMed  Google Scholar 

Ferris RL, Blumenschein GJ, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. The New England J Med. 2016;375:1856–67.

Article  Google Scholar 

Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol : Off J Eur Soc Med Oncol. 2020;31:942–50.

Article  CAS  Google Scholar 

Larkins E, Blumenthal GM, Yuan W, He K, Sridhara R, Subramaniam S, et al. FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. The Oncol. 2017;22:873–8.

Article  CAS  Google Scholar 

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. The New England J Med. 2008;359:1116–27.

Article  CAS  Google Scholar 

Gaździcka J, Gołąbek K, Strzelczyk JK, Ostrowska Z. Epigenetic modifications in head and neck cancer. Biochem Gen. 2020;58:213.

Article  Google Scholar 

Seto E, in MY-CSH perspectives, 2014 undefined. Erasers of histone acetylation: the histone deacetylase enzymes. cshperspectives.cshlp.orgE Seto, M YoshidaCold Spring Harbor perspectives in biology, 2014•cshperspectives.cshlp.org [Internet]. [cited 2023 Sep 23]; Available from: https://cshperspectives.cshlp.org/content/6/4/a018713.short

Vatsa PP, Jindal Y, Bhadwalkar J, Chamoli A, Upadhyay V, Mandoli A. Role of epigenetics in OSCC: an understanding above genetics. Med Oncol. 2023;40:4.

Article  Google Scholar 

Rastogi B, Raut SK, Panda NK, Rattan V, Radotra BD, Khullar M. Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis. Mol Cell Biochem. 2016;415:183–96.

Article  CAS  PubMed  Google Scholar 

Chen Y, Kao S, Wang H, Cancer MY-, 2013 undefined. Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma. Wiley Online LibraryYW Chen, SY Kao, HJ Wang, MH Yang Cancer, 2013•Wiley Online Library. 2013;119:4259–67.

Webber LP, Wagner VP, Curra M, Vargas PA, Meurer L, Carrard VC, et al. Hypoacetylation of acetyl-histone H3 (H3K9ac) as marker of poor prognosis in oral cancer, Histopathology, Blackwell Publishing Ltd; 2017;71:278–86.

Noguchi A, Li X, Kubota A, Kikuchi K, Kameda Y, Zheng H, et al. SIRT1 expression is associated with good prognosis for head and neck squamous cell carcinoma patients. Oral Surgery, Oral Med, Oral Pathol Oral Radiol. 2013;115:385–92.

Article  Google Scholar 

Giudice FS, Pinto DS, Nör JE, Squarize CH, Castilho RM. Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PLoS ONE. 2013;8:e58672.

Article  CAS  PubMed  Google Scholar 

Yoo YG, Kong G, Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. The EMBO J EMBO J. 2006;25:1231–41.

Article  CAS  PubMed  Google Scholar 

Geng H, Harvey CT, Pittsenbarger J, Liu Q, Beer TM, Xue C, et al. HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia. The J Biol Chem. 2011;286:38095.

Article  CAS  PubMed  Google Scholar 

Chen S, Yin C, Lao T, Liang D, He D, Wang C, et al. AMPK-HDAC5 pathway facilitates nuclear accumulation of HIF-1α and functional activation of HIF-1 by deacetylating Hsp70 in the cytosol. Cell Cycle. 2015;14:2520–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

KrennHrubec K, Marshall B MH-B&, 2007 undefined. Design and evaluation of “Linkerless” hydroxamic acids as selective HDAC8 inhibitors. Elsevier [Internet]. [cited 2023 Sep 26]; Available from: https://www.sciencedirect.com/science/article/pii/S0960894X07002612

Chang CC, Lin BR, Chen ST, Hsieh TH, Li YJ, Kuo MYP. HDAC2 promotes cell migration/invasion abilities through HIF-1α stabilization in human oral squamous cell carcinoma. J Oral Pathol Med. 2011;40:567–75.

Article  CAS  PubMed  Google Scholar 

Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol. 2006;26:2019–28.

Article  CAS  PubMed  Google Scholar 

Lim J, Lee Y, Chun Y, Chen J, Kim J, cell JP-M, et al. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1α. cell.comJH Lim, YM Lee, YS Chun, J Chen, JE Kim, JW ParkMolecular cell, 2010•cell.com. 2010;38:864–78.

Li Y, Seto E. HDACs and HDAC Inhibitors in Cancer Development and therapy cold spring harbor perspectives in medicine, Cold spring harbor laboratory press; 2016. 6:a026831

Gama R, Arantes L, Reports BS-S, 2021 undefined. Evaluation of acetylation and methylation in oral rinse of patients with head and neck cancer history exposed to valproic acid. nature.comRR Gama, LMRB Arantes, BP Sorroche, P De Marchi, ME Melendez, RS CarvalhoScientific Reports, 2021•nature.com [Internet]. [cited 2023 Sep 25]; Available from: https://www.nature.com/articles/s41598-021-95845-3

West A, clinical RJ-TJ of, 2014 undefined. New and emerging HDAC inhibitors for cancer treatment. Am Soc Clin InvestigAC West, RW JohnstoneThe Journal of clinical investigation, 2014•Am Soc Clin Investig [Internet]. [cited 2023 Sep 25]; Available from: https://www.jci.org/articles/view/69738

Garcia-Manero G, Blood HY-, Journal T, 2008 undefined. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid ) in patients with advanced leukemias and myelodysplastic. ashpublications.orgG Garcia-Manero, H Yang, C Bueso-Ramos, A Ferrajoli, J Cortes, WG Wierda, S FaderlBlood, The Journal of the American Society of Hematology, 2008•ashpublications.org [Internet]. [cited 2023 Sep 25]; Available from: https://ashpublications.org/blood/article-abstract/111/3/1060/25498

Ma J, Guo X, Zhang S, Liu H, Lu J, Dong Z, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines. Mol Med Rep. 2015;11:4525–31.

Article  CAS  PubMed  Google Scholar 

Karami A, Fakhri S, Kooshki L, Khan H. Polydatin: pharmacological mechanisms, therapeutic targets, biological activities, and health benefits. Molecules [Internet]. 2022;27:6474.

Article  CAS  PubMed  Google Scholar 

Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells.

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. 2000;28:235–42.

Butt SS, Badshah Y, Shabbir M, Rafiq M. Molecular docking using chimera and Autodock Vina software for Nonbioinformaticians Corresponding Author : 2020;1:1–25.

Huang J, MacKerell AD Jr. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J Comput Chem. 2013;34:2135–45.

Article  CAS  PubMed  Google Scholar 

Bekker H, Berendsen H, Dijkstra E, Achterop S, Vondrumen R, Vanderspoel D, et al. (1993) Gromacs - a parallel computer for molecular-dynamics simulations: 4th international conference on computational physics pc, Degroot R, Nadrchal J, (Eds.) Physics Computing, ’92, World scientific publishing, Singapore, 252–625.

End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design | Chemical Reviews [Internet]. [cited 2023 Dec 23]. Available from: https://pubs.acs.org/doi/full/https://doi.org/10.1021/acs.chemrev.9b00055?casa_token=0UMfj-53wdwAAAAA%3ADapUrVsDW68TmucXKX5Q-Zrv3x7d6Xrngvg08yx1koGQ6LQa9Gy6EalqA6flXyHtx3NqXfVXH2hgqaKH

Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14(33–8):27–8.

Google Scholar 

Grant BJ, Rodrigues APC, ElSawy KM, McCammon JA, Caves LSD. Bio3d: an R package for the comparative analysis of protein structures. Bioinformatics. 2006;22:2695–6.

Article  CAS  PubMed  Google Scholar 

Miller BRI, McGee TD Jr, Swails JM, Homeyer N, Gohlke H, Roitberg AE. MMPBSA. py an efficient program for end-state free energy calculations. J Chem Theory Comput. 2012;8:3314–21.

Article  CAS  PubMed  Google Scholar 

Sun H, Duan L, Chen F, Liu H, Wang Z, Pan P, et al. Assessing the performance of MM/PBSA and MM/GBSA methods. 7. Entropy effects on the performance of end-point binding free energy calculation approaches. Phys Chem Chem Phys. 2018;20:14450–60.

Article  CAS  PubMed  Google Scholar 

Lee SK, Lee IH, Kim HJ, Chang GS, Chung JE, No KT. The PreADME Approach: web-based program for rapid prediction of physico-chemical, drug absorption and drug-like properties EuroQSAR 2002 designing drugs and crop protectants: processes, problems and solutions. USA: Blackwell Publishing; 2003. p. 418–20.

Google Scholar 

Lee SK, Lee IH, Kim HJ, Chang GS, Chung JE, No KT. The preADME approach: web-based program for rapid prediction processes, problems, and solutions. Malden, MA, USA: Blackwell Publishing; 2003.

Google Scholar 

Bhat TA, Moon JS, Lee S, Yim D, Singh RP. Inhibition of angiogenic attributes by decursin in endothelial cells and ex vivo rat aortic ring angiogenesis model. Indian J Exp Biol. 2011;49:848–56.

CAS  PubMed  Google Scholar 

Bhat TA, Nambiar D, Tailor D, Pal A, Agarwal R, Singh RP. Acacetin inhibits in vitro and in vivo angiogenesis and downregulates Stat signaling and VEGF expression. Cancer Prev Res (Phila). 2013;6:1128–39.

Article  CAS  PubMed  Google Scholar 

Akash S, Bayıl I, Rahman MA, Mukerjee N, Maitra S, Islam MR, et al. Target specific inhibition of West Nile virus envelope glycoprotein and methyltransferase using phytocompounds: an in silico strategy leveraging molecular docking and dynamics simulation. Front Microbiol. 2023;14:1189786.

Article  PubMed  Google Scholar 

Hu W-H, Wang H-Y, Kong X-P, Xiong Q-P, Poon KK-M, Xu L, et al. Polydatin suppresses VEGF-induced angiogenesis through binding with VEGF and inhibiting its receptor signaling. FASEB J. 2019;33:532–44.